



COMPANY OVERVIEW

Oragenics, Inc. is a biotechnology company specializing in nasal drug delivery for neurological and rare diseases. The company's lead program, ONP-002, is an intranasal neurosteroid in development for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion.

At the core of Oragenics' innovation is its proprietary intranasal drug delivery platform, designed to enhance bioavailability, precision targeting, and ease of administration. This technology enables efficient, non-invasive drug delivery to the brain, reducing systemic exposure and side effects. Beyond concussion, the platform has potential applications across a range of neurological conditions, including neurodegenerative diseases, acute brain injuries, and central nervous system disorders.

By integrating cutting-edge therapeutics with advanced drug delivery technology, Oragenics aims to transform the treatment landscape for brain-related health conditions, addressing significant unmet medical needs.

RECENT NEWS

Oragenics Q3 2025 Shareholder Update

Nov 12 2025, 8:30 AM EST

STOCK OVERVIEW

Symbol	OGEN
Exchange	NYSE American
Market Cap	3.66m
Last Price	\$0.8791
52-Week Range	\$0.735 - \$18.897

01/13/2026 09:00 PM EST

INVESTOR RELATIONS

Janet Huffman
ir@oragenics.com

MANAGEMENT TEAM

Janet Huffman

Chief Executive Officer & Chief Financial Officer

Mark Gandolfo

Project Manager

James P. Kelly, MA, MD, FAAN, FANA

Chief Medical Officer

William "Frank" Peacock MD

Chief Clinical Officer

ORAGENICS, INC.

1990 Main Street
Suite 750
Sarasota, FL 34236
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.